China is Expected to Become the Fifth Largest Drug Market in the World By 2010 - a Comprehensive Guidebook for Foreign Pharmaceutical Companies
Posted on: Monday, 15 May 2006, 21:06 CDT
Research and Markets (http://www.researchandmarkets.com/reports/c34128) has announced the addition of Chinese Latest Regulations for Imported Drug Registration: A Comprehensive Guidebook for Foreign Pharmaceutical Companies to their offering.
China possesses a fourth population in the world and has one of the largest drug markets round the world. By 2003, sales on the Chinese drug market have reached $6.1 billion dollars, an increase of 2.3 fold over 1998 level. A series of factors, such as an increasingly ageing population, the accelerating growth of the urban population as well as the expansion of healthcare covering urban and rural, will expand the Chinese drug market with a growth rate of 20-25 percent per annum in the next five years. China is expected to become the fifth largest drug market in the world by 2010.
Since the reform and open door policy implemented by Chinese authorities in the late 1970s, the Chinese drug market began opening up to the world step by step, which gave a fillip to the imported drugs from overseas pharmaceutical manufacturers and producers. By 2003, sales of imported drugs have shared one fifth on the Chinese drug market. As China joins the World Trade Organization (WTO) and integrates more completely into the global economy, it will further open the door to a lucrative drug market for overseas pharmaceutical companies. More and more overseas pharmaceutical manufacturers and producers expect to enter such drug market and seize a larger part of this drug market. To enter such a lucrative drug market, the first obstacle faced by overseas pharmaceutical manufacturers and producers is how to file the application for their imported drug registration with Chinese pharmaceutical authorities. The latest "Measures for the Administration of Drug Registration" have entered into force since May 1, 2005. These "Measures" provide detailed requirements and procedures of application and approval for imported drug registration.
This China Pharmaceutical Guidebook Series is based upon these measures. The aim of this guidebook series is to guide overseas pharmaceutical manufacturers and producers to achieve successful application and approval for their imported drug registration. In this guidebook series, overseas pharmaceutical manufacturers and producers can easily find out every answer that they will meet question during process of application and approval for their imported drug registration.
For more information visit http://www.researchandmarkets.com/reports/c34128
Source: Business Wire
Related Articles
- China's Breast Cancer Drug Market Will Grow From $165 Million in 2008 to $298 Million In 2013
- China's Rheumatoid Arthritis Drug Market Will More than Double by 2013
- Chinese Non-Small-Cell Lung Cancer Drug Market Will More Than Double by 2013
- Chinese Colorectal Cancer Drug Market Will More Than Double by 2012
- China's Hepatitis B Virus Drug Market Will Grow to $800 Million By 2012
- China's Renal Cell Carcinoma Drug Market Will Grow More Than Five-Fold By 2012
- Introducing the 2007 Chinese Cell and Panel Manufacturers Market Survey
- Greater China Media & Entertainment Corporation Obtains Control of Local Chinese Company to Produce Movies and TV Series
- Shot in the Arm: South Korean Government Promises a Hike in Drug and Pharmaceutical R&D Expenditure
- Expanding Prevalent Population Will Drive Dramatic Growth for the Asthma Drug Market in China
 |
 |
User Comments (0)
RSS Feeds